News | May 18, 2025
Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Subscribe To Our Newsletter & Stay Updated
